JP2015504430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504430A5 JP2015504430A5 JP2014542299A JP2014542299A JP2015504430A5 JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5 JP 2014542299 A JP2014542299 A JP 2014542299A JP 2014542299 A JP2014542299 A JP 2014542299A JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- allele
- seq
- patient
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ3702011 | 2011-11-21 | ||
| IQ370/2011 | 2011-11-21 | ||
| US201261624564P | 2012-04-16 | 2012-04-16 | |
| US61/624,564 | 2012-04-16 | ||
| PCT/US2012/041310 WO2013077907A1 (en) | 2011-11-21 | 2012-06-07 | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504430A JP2015504430A (ja) | 2015-02-12 |
| JP2015504430A5 true JP2015504430A5 (enExample) | 2015-07-23 |
Family
ID=48470189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542299A Pending JP2015504430A (ja) | 2011-11-21 | 2012-06-07 | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150064193A1 (enExample) |
| EP (1) | EP2783014A1 (enExample) |
| JP (1) | JP2015504430A (enExample) |
| KR (1) | KR20140097178A (enExample) |
| CN (1) | CN104011223A (enExample) |
| AR (1) | AR086907A1 (enExample) |
| AU (1) | AU2012341081B2 (enExample) |
| BR (1) | BR112014012101A2 (enExample) |
| CA (1) | CA2856252A1 (enExample) |
| MX (1) | MX2014006158A (enExample) |
| RU (1) | RU2014125071A (enExample) |
| WO (1) | WO2013077907A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| MX356279B (es) | 2010-10-08 | 2018-05-22 | Novartis Ag Star | Métodos para el tratamiento de soriasis usando antagonistas de il-17. |
| AU2011325134B2 (en) | 2010-11-05 | 2014-10-23 | Novartis Ag | Methods of treating rheumatoid arthritis using IL-17 antagonists |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015176031A2 (en) | 2014-05-15 | 2015-11-19 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| FI3191120T3 (fi) | 2014-09-10 | 2024-07-10 | Novartis Ag | Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| WO2016118921A1 (en) * | 2015-01-24 | 2016-07-28 | Abbvie, Inc. | Compositions and methods for treating psoriatic arthritis |
| CN108350068A (zh) | 2015-10-27 | 2018-07-31 | Ucb生物制药私人有限公司 | 使用抗-il-17a/f抗体的治疗方法 |
| MA55149A (fr) * | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| US20200385453A1 (en) * | 2019-06-04 | 2020-12-10 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody |
| EP4031570A1 (en) * | 2019-09-20 | 2022-07-27 | Novartis AG | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists |
| EP4305062A1 (en) * | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
| BR112023018353A2 (pt) * | 2021-03-12 | 2024-02-06 | Janssen Biotech Inc | Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23 |
| CN114427001A (zh) * | 2022-01-29 | 2022-05-03 | 中日友好医院(中日友好临床医学研究所) | 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| PL1963368T6 (pl) | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| CA2637166A1 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies for treating cancer |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| BRPI0813262A2 (pt) * | 2007-06-20 | 2015-04-14 | Schering Corp | Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a |
| CA2737636A1 (en) | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| WO2011014349A1 (en) * | 2009-07-28 | 2011-02-03 | Centocor Ortho Biotech Inc. | Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis |
| MX356279B (es) * | 2010-10-08 | 2018-05-22 | Novartis Ag Star | Métodos para el tratamiento de soriasis usando antagonistas de il-17. |
| TW201307845A (zh) * | 2010-12-13 | 2013-02-16 | Novartis Ag | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 |
-
2012
- 2012-06-07 RU RU2014125071/10A patent/RU2014125071A/ru not_active Application Discontinuation
- 2012-06-07 CA CA2856252A patent/CA2856252A1/en not_active Abandoned
- 2012-06-07 CN CN201280057295.5A patent/CN104011223A/zh active Pending
- 2012-06-07 EP EP12727081.7A patent/EP2783014A1/en not_active Withdrawn
- 2012-06-07 JP JP2014542299A patent/JP2015504430A/ja active Pending
- 2012-06-07 MX MX2014006158A patent/MX2014006158A/es unknown
- 2012-06-07 US US14/358,504 patent/US20150064193A1/en not_active Abandoned
- 2012-06-07 BR BR112014012101A patent/BR112014012101A2/pt not_active IP Right Cessation
- 2012-06-07 WO PCT/US2012/041310 patent/WO2013077907A1/en not_active Ceased
- 2012-06-07 AU AU2012341081A patent/AU2012341081B2/en not_active Ceased
- 2012-06-07 KR KR1020147013196A patent/KR20140097178A/ko not_active Withdrawn
- 2012-06-11 AR ARP120102076A patent/AR086907A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014125071A (ru) | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa | |
| RU2014146594A (ru) | Способы лечения анкилозирующего спондилита с использованием антагонистов il-17 | |
| US12269873B2 (en) | Signature of TL1A (TNFSF15) signaling pathway | |
| JP2017513937A5 (enExample) | ||
| RU2016144177A (ru) | Способы избирательного лечения астмы с использованием антагонистов il-13 | |
| AU2018286624A1 (en) | Identification of polynucleotides associated with a sample | |
| EP2848702A1 (en) | Disease markers and uses thereof | |
| EP2443257A1 (en) | Method of determining response to treatment with immunomodulatory composition | |
| Dall'Ozzo et al. | Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR | |
| JP2009039107A5 (enExample) | ||
| van Sorge et al. | Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms | |
| Chae et al. | The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population | |
| JP2017519498A5 (enExample) | ||
| WO2016022589A2 (en) | Methods for treating multiple myeloma | |
| EP3390449A1 (en) | Antibodies to risperidone and use thereof | |
| CN102808030B (zh) | 单核苷多态性rs3888188在检测结核病易感性中的应用 | |
| US20210148910A1 (en) | Compositions and methods for treatment of atopic dermatitis and treatment selection | |
| Namboodiri et al. | Differential inhibition of trastuzumab-and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes | |
| JP2019520355A5 (enExample) | ||
| CN109576363B (zh) | 一种人abcc2基因多态性检测的引物设计方法及试剂盒 | |
| US20100092468A1 (en) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents | |
| WO2013107005A1 (zh) | 人稀有血型的多重pcr检测方法和试剂盒 | |
| Jiao et al. | Gene analysis of two cases with CisAB/B blood subgroup | |
| KR20070004082A (ko) | Ｆｃ 수용체 다형성의 확인을 위한 핵산 기반 분석 | |
| KR20220061425A (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 |